Q1 FY2015

(Fiscal Year Ending March 31, 2016)

Financial Results Presentation

Eisai Co., Ltd.

July 31, 2015

hhc

human health care



Q1 FY2015

(Billion yen, %)

	April - June 2014		April - June 2015		
	Results	%	Results	%	YoY
Revenue	132.8	100.0	139.2	100.0	105
Cost of sales	48.1	36.2	49.4	35.5	103
Gross profit	84.7	63.8	89.8	64.5	106
R&D expenses	29.1	21.9	32.7	23.5	112
SG&A expenses	47.2	35.5	49.9	35.8	106
Other income & expenses	0	0.0	0.4	0.3	1,114
Operating profit	8.5	6.4	7.6	5.5	90
Profit for the period	5.7	4.3	5.5	4.0	96

Q1 FY2015 average exchange rates:

USD: 121.36 yen (+18.8% YoY), EUR: 134.15 yen (-4.2% YoY), GBP: 186.11 yen (+8.3% YoY), RMB: 19.56 yen (+19.3% YoY)

Breakdown of Revenue Migration

Steady growth of global brands and China/Asia*1 regions



Expansion of global brands*2	
Halaven	+1.7
LENVIMA	+1.1
Fycompa	+0.8
BELVIQ®	+0.5

Expansion of business*3 in China/Asia	
China	+3.8
Asia	+1.3

Japan pharmaceutical business	
Halaven	+0.3
LENVIMA	+0.2
Lunesta, HUMIRA and Lyrica*4	+2.1
Aricept	-2.0
Pariet	-2.4
Others	-2.2

* Figures shown in breakdown of revenue migration above are approximate

*1: Mainly South Korea, Taiwan, Hong Kong, India and ASEAN
*2: Excluding revenue of Japan pharmaceutical business
*3: Excluding revenue of global brands
*4: Alliance revenue

Margin

<Change in long-term borrowings interest rates[*2]>



Leverage

<Change in amount of interest-bearing debts>



Turnover

<Change in cash position>



Enhancement of Shareholder Value through Strong Balance Sheet

Stable Dividend Policy

Sustain 150 yen dividend per share

Forecast for FY2015 (IFRS)

(Billion yen, %)

	FY2014		FY2015		
	Results	%	Forecast	%	YoY
Revenue	548.5	100.0	556.5	100.0	101
Cost of sales	193.6	35.3	196.0	35.2	101
Gross profit	354.9	64.7	360.5	64.8	102
R&D expenses	131.9	24.1	126.5	22.7	96
SG&A expenses and others*	194.6	35.5	188.0	33.8	97
Operating profit	28.3	5.2	46.0	8.3	162
Profit for the period	43.5	7.9	27.0	4.9	62
EPS (yen)	151.6		93.8		62
ROE (%)	7.7		4.5		
DOE (%)	7.6		7.2		
Dividends (yen)	150		150		

* SG&A expenses + other income and expenses

F2 14.04 TFY2014 average exchange rate: USD 109.92 yen, EUR 138.18560ET2-3(c)-5(hc)-5(hc)-5.9 -e .4 7pee0de0p9e4r7iode

hhc human health care

Return to Growth Trajectory

Progress and achievements to date

4 global brands

Japan pharmaceutical business

China/Asia*

Next-generation
Alzheimer's disease treatments

* Mainly South Korea, Taiwan, Hong Kong, India and ASEAN

Halaven Achieved Quarterly Revenue of Over 10B Yen for the First Time

Q1 revenue of 10.1B yen achieved 124% YoY

Japan
1.8B yen
117% YoY

- Duet formation* effective in increased contribution to patient
- Expand contribution in earlier-line treatment

Americas
4.4B yen
116% YoY

- Launched in Brazil (Nov. 2014) and Mexico (Apr. 2015), in addition to the U.S. and Canada

EMEA
3.4B yen
133% YoY

Asia
0.4B yen
199% YoY



Accelerate growth in revenue through approval for the indication of 2nd line treatment for metastatic breast cancer in EMEA and Asia

* Sales force collaboration between approx. 630 Integrated Community *hhc* unit sales force and approx. 130 Oncology *hhc* unit sales force

Presented at 2015 ASCO Annual Meeting
Abstract No.: LBA10502, Patrick Schöffski *et al.* Used by the permission of the author and of the American Society of Clinical Oncology
In this study, the most common treatment-emergent adverse events observed in the eribulin arm were fatigue or asthenia, neutropenia, nausea, alopecia, and peripheral

LENVIMA

Launches Achieved in the U.S., Japan and EU[*1]

Over 900 patients have been administered LENVIMA in the regions[*2]

Launched in Japan on May 20, 2015

LENVIMA

2nd Line Phase II Study in Renal Cell Carcinoma*[1,2]

Favorable results detailed in ASCO 2015 oral presentation



LENVIMA*1

Maximize the potential through clinical studies across tumors

Hepatocellular carcinoma*2 1st line Phase III study	Renal cell carcinoma*2 2nd line Phase II study
Steadily ongoing Achieved 940 subject enrolled in July 2015 Plan to submit in FY2016	Obtained favorable topline results presented at ASCO 2015 Breakthrough Therapy pathway designation granted by FDA in July 2015
Combination regimens*2 with immune checkpoint inhibitor KEYTRUDA (pembrolizumab)	Endometrial cancer*2 2nd line
Initiated Phase Ib/II study in lung cancer, melanoma, head and neck cancer, bladder cancer, renal cancer and endometrial cancer in July 2015	Following findings in Phase II study (Study 204) suggesting plasma angiopoietin-2 as potential biomarker candidate for measuring clinical efficacy, currently making preparations for new Phase IIb study to develop companion diagnostics using plasma angiopoietin-2

*1: Indicated in the U.S. for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer; indicated in Japan for the treatment of unresectable thyroid cancer; indicated in Europe for the treatment of adult patients with progressive, locally advanced or metastatic differentiated (papillary, follicular, Hürthle cell) thyroid carcinoma (DTC) refractory to radioactive iodine (RAI)

*2: Currently under investigation

BELVIQ®

Seek continuous growth and profitability

Q1 Results: Revenue 1.5B yen (145 YoY)
SG&A controlled to approx. 60% YoY

Acceleration of Laser-focused commercial mix

Seek effective and efficient marketing
through acquired experience and knowledge

Sales force optimization (Approx. 90 Eisai sales force and 230 syndicated sales force*1)

Optimized to approx. 320 sales force
Focused sales force activity to high prescribers of obesity treatment agents

Patient support program

Improve affordability for patients through “Pay no more than $75” program for eligible cash patients

Targeted consumer activities

Achieve greater awareness through DRTV*2 focused on high seasons

Revenue growth of BELVIQ®



*1 Seek cost optimization by utilizing syndicated sales force promoting BELVIQ® and another product from another company
*2 Direct Response Television

Japan Pharmaceutical Business



3 Projects Based on A-beta Hypothesis Toward Realization of Preemptive Medicine in Alzheimer's Disease

BAN2401*1

Anti-A-beta protofibrils antibody

Phase II study is ongoing

7th interim analysis of Phase II study was conducted in June 2015 (500 subject)
Topline result of Phase II study is anticipated in Q4 FY2015
(650 minimum subject)

E2609*1

BACE (Beta-secretase) inhibitor developed in-house

Safety stage (Stage A) in Phase II study is ongoing

Topline result of Stage A is anticipated in Q4 FY2015

Aducanumab (BIIB037*1)

Anti-A-beta antibody by Biogen
(Eisai retains option)

Pre-specified interim analysis of Phase Ib data was presented at AAIC*2

Overall results show a statistically significant dose-dependent reduction in amyloid plaque, a dose-dependent slowing of cognitive decline, and acceptable safety

Phase III studies are ongoing

Two 18-month studies in patients with early AD
Primary endpoint: CDR-SB score*3

*1: Investigational *2: AAIC: Alzheimer's Association International Conference 2015
*3: Clinical Dementia Rating-Sum of Boxes: Scale for disease diagnosis

Strategies to Achieve FY2015 Business Plan

Fycompa®

Return to growth trajectory
in both revenue and operating profit in FY2015

Reference Data



Operating Profit by Reporting Segment

	April - June 2014			April - June 2015			
	Results	%	% of revenue	Results	%	% of revenue	YoY
Japan*1	33.9	84.2	46.0	31.3	72.9	44.9	92
Americas*2	0.1	0.2	0.3	2.1	4.9	7.1	2,446
China	2.7	6.8	29.7	4.2	9.8	32.5	155
Asia*3	1.6	3.9	22.3	2.3			

Performance of Japan Pharmaceutical Business

(Billion yen, %)

	April - June 2014		April - June 2015		
	Results	%	Results	%	YoY
Revenue	73.7	100.0	69.8	100.0	95
Prescription medicines	66.0	89.5	61.5	88.1	93
Aricept	13.4	18.2	11.4	16.4	85
Pariet[*1]	10.8	14.6	8.4	12.0	78
Humira	7.8	10.5	8.1	11.6	104
Lyrica[*2]	4.3	5.8	5.7	8.2	133
Methycobal	6.3	8.6	5.5	8.0	88
Warfarin	2.4	3.3	2.1	3.0	86
Halaven	1.6	2.1	1.8	2.6	117
Actonel	1.9	2.5	1.7	2.5	92
Lunes					

Performance of Americas Pharmaceutical Business

(Billion yen, %)

	April - June 2014		April - June 2015			
	Results	%	Results	%	YoY	
Revenue	25.4	100.0	29.8	100.0	117	[99]

hhc human health care

Performance of China and Asia Pharmaceutical Business

<China>

(Billion yen, %)

	April - June 2014		April - June 2015			
	Results	%	Results	%	YoY	
Revenue	9.2	100.0	12.9	100.0	141	[119]
Methycobal	4.0	43.9	5.1	39.4	127	[106]
Stronger Neo-Minophagen C / Glycyron Tablets	1.3	14.4	2.3	17.5	172	[144]
Aricept	1.1	11.9	1.4	10.6	126	[106]
Pariet	0.7	7.7	0.9	7.0	129	[108]
Segment profit	2.7	29.7	4.2	32.5	155	[125]

[ ] based on local currency

<Asia*>

(Billion yen, %)

	April - June 2014		April - June 2015			
	Results	%	Results	%	YoY	
Revenue	7.1	100.0	8.6	100.0	121	[108]
Aricept	2.1	29.9	2.6	30.5	124	[110]
Humira	2.0	27.7	2.2	25.8	113	[100]
Methycobal	0.6	8.3	0.9	10.1	148	[130]
Pariet	0.8	11.8	0.8	9.6	98	[87]
Halaven	0.2	3.1	0.4	5.0	199	[175]
Segment profit	1.6	22.3	2.3	26.4	144	[122]

* Mainly South Korea, Taiwan, Hong Kong, India and ASEAN

[ ] based on local currency

Performance of EMEA* Pharmaceutical Business and Consumer Healthcare Business (mainly OTC products)

<EMEA*>

(Billion yen, %)

	April - June 2014		April - June 2015			
	Results	%	Results	%	YoY	
Revenue	8.8	100.0	10.2	100.0	115	[117]
Halaven	2.6	29.2	3.4	33.7	133	[134]
Zonegran	1.9	22.0	2.0	20.0	104	[107]
Zebinix	0.7	7.8	0.9	8.8	130	[135]
Fycompa	0.5	6.1	0.7	7.0	132	[134]
Inovelon	0.5	6.1	0.5	5.4	102	[104]
Lenvima			0	0.1		
Segment profit	1.1	12.2	1.9	18.3	173	[196]

* Europe, Middle East, Africa, Russia, and Oceania

[ ] based on local currency

<Consumer Healthcare Business (Japan)>

(Billion yen, %)

	April - June 2014		April - June 2015		
	Results	%	Results	%	YoY
Revenue	3.8	100.0	4.0	100.0	107
Chocola BB group	2.5	66.3	2.5	62.6	101
Segment profit*	(0.4)		0.6	14.4	

From the consolidated fiscal year ending March 31, 2016, the management structure for part of the costs in Japan was revised and the method for allocation of SG&A expenses changed as a result. As such, the “Japan pharmaceutical business” and “Consumer Healthcare Business-Japan” segment profit (loss) as well as “Group headquarters’ management costs and other expenses” figures stated for the previous fiscal year ended March 31, 2015, have also been restated to reflect these changes